Published in Eur J Immunol on December 05, 2012
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant (2014) 1.20
Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Front Immunol (2014) 1.04
Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood (2015) 0.99
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant (2015) 0.80
In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol (2015) 0.78
Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation? Transl Stroke Res (2016) 0.78
Transcriptome signature for dampened Th2 dominance in acellular pertussis vaccine-induced CD4(+) T cell responses through TLR4 ligation. Sci Rep (2016) 0.78
PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight (2016) 0.76
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med (2016) 0.76
Triptolide Upregulates Myocardial Forkhead Helix Transcription Factor p3 Expression and Attenuates Cardiac Hypertrophy. Front Pharmacol (2016) 0.75
Development of preclinical models for immunogene therapy of brain cancer: it's not monkey business! Mol Ther (2014) 0.75
FMS-like tyrosine kinase 3 ligand treatment does not ameliorate experimental rapidly progressive glomerulonephritis. PLoS One (2015) 0.75
Immunoglobulin G promotes skin graft acceptance in an immunologically potent rat model. Oncotarget (2016) 0.75
Intratumoral STING activation with T cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res (2017) 0.75
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A (2006) 3.19
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
RNAdb--a comprehensive mammalian noncoding RNA database. Nucleic Acids Res (2005) 2.84
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood (2008) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood (2002) 2.30
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology (2014) 2.09
A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci U S A (2006) 2.00
New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. Vaccine (2013) 1.96
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) (2008) 1.78
Genome-wide identification of long noncoding RNAs in CD8+ T cells. J Immunol (2009) 1.73
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol (2002) 1.67
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8⁺ T cells. Nat Immunol (2012) 1.62
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res (2014) 1.40
Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU Int (2013) 1.39
Complementary signaling through flt3 and interleukin-7 receptor alpha is indispensable for fetal and adult B cell genesis. J Exp Med (2003) 1.39
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood (2004) 1.39
An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res (2007) 1.38
GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood (2006) 1.34
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity (2008) 1.30
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell (2013) 1.28
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 1.27
The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol (2009) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action. Proc Natl Acad Sci U S A (2010) 1.25
Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity (2005) 1.24
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol (2010) 1.21
Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling. Immunol Cell Biol (2007) 1.21
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines (2007) 1.20
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res (2013) 1.18
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells. J Virol (2003) 1.16
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology (2012) 1.16
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development. Int Immunol (2005) 1.15
Immunoproteasome subunit deficiencies impact differentially on two immunodominant influenza virus-specific CD8+ T cell responses. J Immunol (2006) 1.14
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol (2013) 1.12
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A (2002) 1.11
Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin (2009) 1.10
Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J Biol Chem (2004) 1.10